Study details
Enrolling now
CD19-CD22 Bispecific CAR T Cell Therapy for Pediatric Leukemia
St. Jude Children's Research Hospital
NCT IDNCT06777979ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
30
Study length
about 5.8 years
Ages
≤21
Locations
1 site in TN
About this study
This trial is testing a new treatment called CD19-CD22 bispecific CAR T cell therapy in children with leukemia. The goal is to see if the treatment is safe and determine the right dose (RP2D) for future studies.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive CD19-CD22 CAR T cell infusion
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
- +1 more
PhasePhase 1
DrugCD19-CD22 CAR T cell infusion
Routeintravenous
Primary goalIncidence of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cell therapy, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, mesna
Drug routes
intravenous, infusion, oral (Oral Tablet)
Endpoints
Primary: Incidence of adverse events
Devices
therapeutic
Body systems
Oncology